[
    {
        "gene_name": "EGFR",
        "variant_name": "S768I",
        "HGVScoding": "c.2303G>T",
        "HGVSprotein": "p.Ser768Ile",
        "position": "chr7:55249005",
        "molecular_consequence": "NON_SYNONYMOUS, NONCODING_CHANGE",
        "tier_level": "1B",
        "dbSNP": "rs121913465",
        "SVIP_status": "Curated",
        "SVIP_confidence_score": 4,
        "variant_id": 17,
        "diseases": [
            {
                "name": "non-small cell lung carcinoma",
                "nb_patients": "88/144",
                "age_distribution": {
                    "<40": 5,
                    "41-60": 30,
                    "61-80": 50,
                    ">80": 3
                },
                "gender_balance": {
                    "male": 60,
                    "female": 40
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "automatic",
                "clinical_significance": "predictive",
                "significance_label": "B",
                "score": 3,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            },
            {
                "name": "lung adenocarcinoma",
                "nb_patients": "56/144",
                "age_distribution": {
                    "<40": 10,
                    "41-60": 23,
                    "61-80": 18,
                    ">80": 5
                },
                "gender_balance": {
                    "male": 65,
                    "female": 35
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "expert",
                "clinical_significance": "predictive / prognostic",
                "significance_label": "A",
                "score": 4,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "prognostic",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            }
        ]
    },
    {
        "gene_name": "EGFR",
        "variant_name": "T790M",
        "HGVScoding": "c.2369C>T,",
        "HGVSprotein": "p.Thr790Met",
        "position": "chr7:55249071",
        "molecular_consequence": "NON_SYNONYMOUS, NONCODING_CHANGE, REGULATORY",
        "tier_level": "1B",
        "dbSNP": "rs121434569",
        "SVIP_status": "Loaded",
        "SVIP_confidence_score": 3,
        "variant_id": 2,
        "diseases": [
            {
                "name": "non-small cell lung carcinoma",
                "nb_patients": "88/144",
                "age_distribution": {
                    "<40": 5,
                    "41-60": 30,
                    "61-80": 50,
                    ">80": 3
                },
                "gender_balance": {
                    "male": 60,
                    "female": 40
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "automatic",
                "clinical_significance": "predictive",
                "significance_label": "B",
                "score": 3,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            },
            {
                "name": "lung adenocarcinoma",
                "nb_patients": "56/144",
                "age_distribution": {
                    "<40": 10,
                    "41-60": 23,
                    "61-80": 18,
                    ">80": 5
                },
                "gender_balance": {
                    "male": 65,
                    "female": 35
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "expert",
                "clinical_significance": "predictive / prognostic",
                "significance_label": "A",
                "score": 4,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "prognostic",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            }
        ]
    },
    {
        "gene_name": "EGFR",
        "variant_name": "L858R",
        "HGVScoding": "c.2573T>G",
        "HGVSprotein": "p.Leu858Arg",
        "position": "chr7:55259515",
        "molecular_consequence": "NON_SYNONYMOUS",
        "tier_level": "1A",
        "dbSNP": "rs121434568",
        "SVIP_status": "Reviewed",
        "SVIP_confidence_score": 3,
        "variant_id": 14,
        "diseases": [
            {
                "name": "non-small cell lung carcinoma",
                "nb_patients": "88/144",
                "age_distribution": {
                    "<40": 5,
                    "41-60": 30,
                    "61-80": 50,
                    ">80": 3
                },
                "gender_balance": {
                    "male": 60,
                    "female": 40
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "automatic",
                "clinical_significance": "predictive",
                "significance_label": "B",
                "score": 3,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            },
            {
                "name": "lung adenocarcinoma",
                "nb_patients": "56/144",
                "age_distribution": {
                    "<40": 10,
                    "41-60": 23,
                    "61-80": 18,
                    ">80": 5
                },
                "gender_balance": {
                    "male": 65,
                    "female": 35
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "expert",
                "clinical_significance": "predictive / prognostic",
                "significance_label": "A",
                "score": 4,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "prognostic",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            }
        ]
    },
    {
        "gene_name": "BRAF",
        "variant_name": "G596R",
        "HGVScoding": "c.1786G>C",
        "HGVSprotein": "p.Gly596Arg",
        "position": "chr7:140453149",
        "molecular_consequence": "NON_SYNONYMOUS",
        "tier_level": 3,
        "dbSNP": "rs121913361",
        "SVIP_status": "Loaded",
        "SVIP_confidence_score": 2,
        "variant_id": 215,
        "diseases": [
            {
                "name": "non-small cell lung carcinoma",
                "nb_patients": "88/144",
                "age_distribution": {
                    "<40": 5,
                    "41-60": 30,
                    "61-80": 50,
                    ">80": 3
                },
                "gender_balance": {
                    "male": 60,
                    "female": 40
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "automatic",
                "clinical_significance": "predictive",
                "significance_label": "B",
                "score": 3,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            },
            {
                "name": "lung adenocarcinoma",
                "nb_patients": "56/144",
                "age_distribution": {
                    "<40": 10,
                    "41-60": 23,
                    "61-80": 18,
                    ">80": 5
                },
                "gender_balance": {
                    "male": 65,
                    "female": 35
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "expert",
                "clinical_significance": "predictive / prognostic",
                "significance_label": "A",
                "score": 4,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "prognostic",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            }
        ]
    },
    {
        "gene_name": "BRAF",
        "variant_name": "V600E",
        "HGVScoding": "c.1799T>A",
        "HGVSprotein": "p.Val600Glu",
        "position": "chr7:140453136",
        "molecular_consequence": "NON_SYNONYMOUS",
        "tier_level": "1A",
        "dbSNP": "rs113488022",
        "SVIP_status": "Reviewed",
        "SVIP_confidence_score": 4,
        "variant_id": 160,
        "diseases": [
            {
                "name": "non-small cell lung carcinoma",
                "nb_patients": "88/144",
                "age_distribution": {
                    "<40": 5,
                    "41-60": 30,
                    "61-80": 50,
                    ">80": 3
                },
                "gender_balance": {
                    "male": 60,
                    "female": 40
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "automatic",
                "clinical_significance": "predictive",
                "significance_label": "B",
                "score": 3,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            },
            {
                "name": "lung adenocarcinoma",
                "nb_patients": "56/144",
                "age_distribution": {
                    "<40": 10,
                    "41-60": 23,
                    "61-80": 18,
                    ">80": 5
                },
                "gender_balance": {
                    "male": 65,
                    "female": 35
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "expert",
                "clinical_significance": "predictive / prognostic",
                "significance_label": "A",
                "score": 4,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "prognostic",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            }
        ]
    },
    {
        "gene_name": "BRAF",
        "variant_name": "K601E",
        "HGVScoding": "c.1801A>G",
        "HGVSprotein": "p.Lys601Glu",
        "position": "chr7:140453134",
        "molecular_consequence": "NON_SYNONYMOUS",
        "tier_level": 2,
        "dbSNP": "rs121913364",
        "SVIP_status": "Curated",
        "SVIP_confidence_score": 3,
        "variant_id": 224,
        "diseases": [
            {
                "name": "non-small cell lung carcinoma",
                "nb_patients": "88/144",
                "age_distribution": {
                    "<40": 5,
                    "41-60": 30,
                    "61-80": 50,
                    ">80": 3
                },
                "gender_balance": {
                    "male": 60,
                    "female": 40
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "automatic",
                "clinical_significance": "predictive",
                "significance_label": "B",
                "score": 3,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            },
            {
                "name": "lung adenocarcinoma",
                "nb_patients": "56/144",
                "age_distribution": {
                    "<40": 10,
                    "41-60": 23,
                    "61-80": 18,
                    ">80": 5
                },
                "gender_balance": {
                    "male": 65,
                    "female": 35
                },
                "pathogenicity": "pathogenic",
                "pathogenicity_level": "expert",
                "clinical_significance": "predictive / prognostic",
                "significance_label": "A",
                "score": 4,
                "evidences": [
                    {
                        "drug": "Erlotinib",
                        "evidence_type": "predictive",
                        "clinical_significance": "resistant",
                        "tier_level": "Tier 1B"
                    },
                    {
                        "drug": "Gefitinib",
                        "evidence_type": "prognostic",
                        "clinical_significance": "sensitive",
                        "tier_level": "Tier 1B"
                    }
                ]
            }
        ]
    }
]
